309 related articles for article (PubMed ID: 26698368)
1. Teratoma: from spontaneous tumors to the pluripotency/malignancy assay.
Bulic-Jakus F; Katusic Bojanac A; Juric-Lekic G; Vlahovic M; Sincic N
Wiley Interdiscip Rev Dev Biol; 2016; 5(2):186-209. PubMed ID: 26698368
[TBL] [Abstract][Full Text] [Related]
2. Of mice and men: teratomas and teratocarcinomas.
Bulić-Jakus F; Ulamec M; Vlahović M; Sincić N; Katusić A; Jurić-Lekć G; Serman L; Kruslin B; Belicza M
Coll Antropol; 2006 Dec; 30(4):921-4. PubMed ID: 17243571
[TBL] [Abstract][Full Text] [Related]
3. Intrinsic factors and the embryonic environment influence the formation of extragonadal teratomas during gestation.
Economou C; Tsakiridis A; Wymeersch FJ; Gordon-Keylock S; Dewhurst RE; Fisher D; Medvinsky A; Smith AJ; Wilson V
BMC Dev Biol; 2015 Oct; 15():35. PubMed ID: 26453549
[TBL] [Abstract][Full Text] [Related]
4. Geminin Is Essential for Pluripotent Cell Viability During Teratoma Formation, but Not for Differentiated Cell Viability During Teratoma Expansion.
Adler-Wailes DC; Kramer JA; DePamphilis ML
Stem Cells Dev; 2017 Feb; 26(4):285-302. PubMed ID: 27821018
[TBL] [Abstract][Full Text] [Related]
5. Teratoma formation of human embryonic stem cells in three-dimensional perfusion culture bioreactors.
Stachelscheid H; Wulf-Goldenberg A; Eckert K; Jensen J; Edsbagge J; Björquist P; Rivero M; Strehl R; Jozefczuk J; Prigione A; Adjaye J; Urbaniak T; Bussmann P; Zeilinger K; Gerlach JC
J Tissue Eng Regen Med; 2013 Sep; 7(9):729-41. PubMed ID: 22438087
[TBL] [Abstract][Full Text] [Related]
6. Distinct developmental ground states of epiblast stem cell lines determine different pluripotency features.
Bernemann C; Greber B; Ko K; Sterneckert J; Han DW; Araúzo-Bravo MJ; Schöler HR
Stem Cells; 2011 Oct; 29(10):1496-503. PubMed ID: 21898681
[TBL] [Abstract][Full Text] [Related]
7. Teratoma Assay for Testing Pluripotency and Malignancy of Stem Cells: Insufficient Reporting and Uptake of Animal-Free Methods-A Systematic Review.
Montilla-Rojo J; Bialecka M; Wever KE; Mummery CL; Looijenga LHJ; Roelen BAJ; Salvatori DCF
Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36835305
[TBL] [Abstract][Full Text] [Related]
8. The tumorigenicity of human embryonic stem cells.
Blum B; Benvenisty N
Adv Cancer Res; 2008; 100():133-58. PubMed ID: 18620095
[TBL] [Abstract][Full Text] [Related]
9. In vivo reprogrammed pluripotent stem cells from teratomas share analogous properties with their in vitro counterparts.
Choi HW; Kim JS; Hong YJ; Song H; Seo HG; Do JT
Sci Rep; 2015 Aug; 5():13559. PubMed ID: 26315499
[TBL] [Abstract][Full Text] [Related]
10. Identification of unsafe human induced pluripotent stem cell lines using a robust surrogate assay for pluripotency.
Polanco JC; Ho MS; Wang B; Zhou Q; Wolvetang E; Mason E; Wells CA; Kolle G; Grimmond SM; Bertoncello I; O'Brien C; Laslett AL
Stem Cells; 2013 Aug; 31(8):1498-510. PubMed ID: 23728894
[TBL] [Abstract][Full Text] [Related]
11. From stem cells to germ cell tumors and back.
Damjanov I
Verh Dtsch Ges Pathol; 2004; 88():39-44. PubMed ID: 16892532
[TBL] [Abstract][Full Text] [Related]
12. The teratoma assay: an in vivo assessment of pluripotency.
Wesselschmidt RL
Methods Mol Biol; 2011; 767():231-41. PubMed ID: 21822879
[TBL] [Abstract][Full Text] [Related]
13. Development of experimental tumors formed by mouse and human embryonic stem and teratocarcinoma cells after subcutaneous and intraperitoneal transplantations into immunodeficient and immunocompetent mice.
Gordeeva OF; Nikonova TM
Cell Transplant; 2013; 22(10):1901-14. PubMed ID: 23051679
[TBL] [Abstract][Full Text] [Related]
14. Reversible transformation and de-differentiation of human cells derived from induced pluripotent stem cell teratomas.
Kamada M; Mitsui Y; Matsuo T; Takahashi T
Hum Cell; 2016 Jan; 29(1):1-9. PubMed ID: 26069211
[TBL] [Abstract][Full Text] [Related]
15. Testicular teratomas: an intersection of pluripotency, differentiation and cancer biology.
Bustamante-Marín X; Garness JA; Capel B
Int J Dev Biol; 2013; 57(2-4):201-10. PubMed ID: 23784831
[TBL] [Abstract][Full Text] [Related]
16. Experimental teratoma: at the crossroad of fetal- and onco-development.
Hultman I; Björk L; Blomberg E; Sandstedt B; Ahrlund-Richter L
Semin Cancer Biol; 2014 Dec; 29():75-9. PubMed ID: 25153353
[TBL] [Abstract][Full Text] [Related]
17. The tumorigenicity of diploid and aneuploid human pluripotent stem cells.
Blum B; Benvenisty N
Cell Cycle; 2009 Dec; 8(23):3822-30. PubMed ID: 19887907
[TBL] [Abstract][Full Text] [Related]
18. Interspecific in vitro assay for the chimera-forming ability of human pluripotent stem cells.
Masaki H; Kato-Itoh M; Umino A; Sato H; Hamanaka S; Kobayashi T; Yamaguchi T; Nishimura K; Ohtaka M; Nakanishi M; Nakauchi H
Development; 2015 Sep; 142(18):3222-30. PubMed ID: 26023098
[TBL] [Abstract][Full Text] [Related]
19. Teratoma generation in the testis capsule.
Peterson SE; Tran HT; Garitaonandia I; Han S; Nickey KS; Leonardo T; Laurent LC; Loring JF
J Vis Exp; 2011 Nov; (57):e3177. PubMed ID: 22158256
[TBL] [Abstract][Full Text] [Related]
20. Isolation of pluripotent neural crest-derived stem cells from adult human tissues by connexin-43 enrichment.
Pelaez D; Huang CY; Cheung HS
Stem Cells Dev; 2013 Nov; 22(21):2906-14. PubMed ID: 23750535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
